InflaRx NV (InflaRx NV) Change In Receivables : $-0.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Change In Receivables?

InflaRx NV's change in receivables for the quarter that ended in Mar. 2024 was $-0.04 Mil. It means InflaRx NV's Accounts Receivable increased by $0.04 Mil from Dec. 2023 to Mar. 2024 .

InflaRx NV's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means InflaRx NV's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

InflaRx NV's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.04 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. InflaRx NV's Days Sales Outstanding for the three months ended in Mar. 2024 was 88.91.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. InflaRx NV's liquidation value for the three months ended in Mar. 2024 was $83.84 Mil.

InflaRx NV Change In Receivables Historical Data

The historical data trend for InflaRx NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Change In Receivables Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

InflaRx NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-0.04

InflaRx NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

InflaRx NV (NAS:IFRX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

InflaRx NV's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.038	/	0.039	*	91
=	88.91

2. In Ben Graham's calculation of liquidation value, InflaRx NV's accounts receivable are only considered to be worth 75% of book value:

InflaRx NV's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	91.213	-	13.409	+	0.75 * 0.038	+	0.5 * 12.01
=	83.84

InflaRx NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.